RIDR-PI-103
RIDR-PI-103 is a reactive oxygen species (ROS) -induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103) . Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].
Product Specifications
CAS Number
2581114-71-6
UNSPSC
12352005
Target
Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ridr-pi-103.html
Purity
98.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CN)NC1=CC(N)=CC=C1OC2=CC=CC(C3=NC4=C(C(N5CCOCC5)=N3)OC6=NC=CC=C64)=C2
Molecular Formula
C27H25N7O4
Molecular Weight
511.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![(3aR-cis)-Hexahydro-2-oxo-4H-furo[3,2-b]pyrrole-4-acetic Acid Ethyl Ester](https://cdn.genprice.uk/products/572/8212988524027/imageurl/trc-h294088-25mg.webp)
(3aR-cis)-Hexahydro-2-oxo-4H-furo[3,2-b]pyrrole-4-acetic Acid Ethyl Ester
